ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2209

Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2148

Impact of Hip Fractures in the Elderly Population: Functional Status, Readmission, and One-Year Mortality

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2429

Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2144

Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 1903

Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2377

Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2408

Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1949

Implementation of Pharmacist-Led Comprehensive Medication Management for Puerto Ricans with Rheumatic Diseases

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2455

Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2207

Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2366

Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1911

Improving Healthcare Access in Underserved Brooklyn Communities: A Comprehensive Multispecialty Patient Navigator Program

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 2432

In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1799

In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2372

Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].